Moderna Stock Gets Modest Analyst Fair Value Boost Tied to Cancer Vaccine Progress

Moderna shares received a modest lift to analyst fair value estimates on October 11, driven by revised projections following the company's ongoing cancer vaccine developments. The revisions come after a broader surge in MRNA stock tied to reports of a U.S. public-private cancer vaccine initiative expected to launch in December, as well as positive melanoma trial data for its mRNA-based cancer vaccine intismeran.

Analyst views on Moderna remain mixed despite the upward adjustments, with some noting that the stock's valuation is still elevated relative to current fundamentals. The fair value revision follows an earlier dramatic move in MRNA shares after the company posted strong late-stage melanoma study results, which had prompted William Blair to upgrade the stock to Outperform. Moderna's recent reentry into the Nasdaq-100 has added further attention to the name.